Uptake and mode of action of drugs used against sleeping sickness

Biochemical Pharmacology

Volumn 61, Issue 1, 2001, Pages 1-5

  Denise, Hubert ^a   Barrett, Michael P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; Drug resistance; Megazol; Nitroheteroc ycles; Sleeping sickness; Trypanosomiasis

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; AMES TEST; DNA MODIFICATION; DRUG ACCUMULATION; DRUG MECHANISM; DRUG TARGETING; DRUG UPTAKE; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA BRUCEI;

EID: 0035185867     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00477-9     Document Type: Article

References (42)

1. Perspectives in research on and control of African trypanosomiasis
2. The fall and rise of sleeping sickness
3. Surface receptors and transporters of Trypanosoma brucei
4. The treatment of human African trypanosomiasis
5. Recent research on the biological activity of suramin
6. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action
7. Anti-sleeping sickness drugs and cancer chemotherapy
8. Pentamidine, a review
9. Arsenical-resistant trypanosomes lack an unusual adenosine transporter
10. The structure and replication of kinetoplast DNA
11. Kinetoplasts play an important role in the drug responses of Trypanosoma brucei
12. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei
13. Mel B in the treatment of human trypanosomiasis
14. Paul Ehrlich; a hundred years of chemotherapy 1891-1991
15. A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity
16. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes
17. Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: Substrate recognition motifs and affinity for trypanocidal drugs
18. An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes
19. Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei
20. Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan
21. The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei brucei
22. Ornithine decarboxylase as an enzyme target for therapy
23. Uptake of α-difluoromethylornithine by Trypanosoma brucei brucei
24. A Trypanosoma brucei mutant resistant to α-difluoromethylornithine
25. Biochemical changes associated with α-difluoromethylornithine uptake and resistance in Trypanosoma brucei
26. Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation
27. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-α-difluoromethylornithine
28. Mechanism of nifurtimox toxicity in different forms of Trypanosoma cruzi
29. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: An open trial in central Zaire
30. Comparative studies of nifurtimox uptake and metabolism by drug-resistant and susceptible strains of Trypanosoma cruzi
31. Sensitivity of parasites to free radical damage by anti-parasitic drugs
32. "Subversive" substrates for the enzyme trypanothione disulfide reductase: Alternative approach to chemotherapy of Chagas disease
33. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections
34. Megazol combined with suramin: A chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice
35. Uptake of the nitroimidazole drug megazol by African trypanosomes
36. Enzymatic reduction studies of nitroheterocycles
37. Inhibition of Trypanosoma cruzi and T. brucei NADH fumarate reductase by benznidazole and anthelmintic imidazole derivatives
38. CL 64,855, a potent anti-Trypanosoma cruzi drug, is also mutagenic in Salmonella/microsome assay
39. Compartmentation of carbohydrate metabolism in trypanosomes
40. Metabolism and functions of trypanothione in the Kinetoplastida
41. Recent advances in identifying and validating drug targets in trypanosomes and leishmania
42. Prospects for antiparasitic drugs. The case of Trypanosoma brucei, the causative agent of African sleeping sickness